65,437 trials
Healthy Volunteers
Primary: Number of Participants With Clinical Laboratory Abnormalities Reported as Treatment-Emergent Adverse Events (TEAEs) — 0; 0; 0; 0 Participants
Parkinson's Disease
Primary: Change From Baseline in the Nonmotor Symptom Severity Scale (NMSS) — -33.5; -2.0 change in scale total score — p=0.0089
Intra-dialytic Hypotension
Primary: Change in Intra-dialytic Decline in Systolic Blood Pressure — 26; 23 mm Hg
Agglutinin Disease, Cold
Primary: Part A: Percentage of Participants With Response to Treatment — 54.2 percentage of participants
Obesity
Primary: Percent Weight Change at Week 72 — -7.16; -5.19 percent weight change — p=0.14
HIV-1 Infections
Primary: Number of Participants With Serious Adverse Events — 0; 1; 26 Participants
Statin-related Muscle Pain · Muscle Aches · Muscle Weakness
Primary: Change in Pre- and Post-phosphocreatine Relaxation Time — 5.58; 5.083 milliseconds
Atopic Dermatitis
Primary: Mean Change in Children's PROMIS Pediatric Itch Short-Form — -0.3; -0.4 score on a scale — p=0.433
Leukemia · Lymphoma
Primary: Number of Transplant Recipients With Successful Engraftment — 70 Participants
Preterm Infant · Full-term Infant
Primary: Alberta Infant Motor Scale - Change in Total Percentile Score — 10; 0 change in percentile rank — p=0.016
Muscle Cramp · Cirrhosis
Primary: Frequency of Muscle Cramps as Assessed by Patient Survey — 1.14; 1.23 score on a scale
T Cell Lymphoma
Primary: Number of Participants With and Without Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
COVID-19 · SARS-CoV-2 · Coronavirus
Primary: Percentage of Clinical Agreement Between NOWDx COVID-19 Test and Emergency Use Authorized or FDA Cleared Comparator. — 91.5; 95.4 percentage of results matching PCR
Pancreatic Cancer
Primary: Progression-free Survival (PFS) — 6.5; 8.4 months
Diabetic Macular Edema
Primary: Change From Baseline in Best-corrected Visual Acuity (BCVA) at Week 52 — 7.3; 10.6; 9.2; 10.5 Scores on a scale — p=<0.001